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Drug orientations within statin-loaded lipoprotein nanoparticles 
by 19F solid-state NMR
Sophie Lau,a Naomi Stanhopea, John Griffina, Eleri Hughesa, David A. Middleton*a
NMR measurements of 19F chemical shift anisotropy and 1H-19F 
dipolar couplings provide unprecedented information on the 
molecular orientations of two fluorine-containing statin drugs 
within the heterogeneous environment of reconstituted high-
density lipoprotein (rHDL) nanoparticles, a drug delivery system 
under clinical investigation. 
Apolipoprotein A-I; solid-state NMR; drug delivery; HDL
The high cost of bringing a new pharmaceutical to market – an 
estimated $2.6 billion - reflects the fact that 85-90 % of drug 
candidates do not progress through clinical trials.1 One reason for 
this high attrition rate is the failure of drugs to engage effectively 
with their molecular target(s) in human patients,2 and this has 
motivated efforts to develop smart, nanoscale formulations to 
lengthen drug circulation times in vivo, access impervious tissue and 
increase the probability of drug-target interactions. Nanoparticle-
mediated drug delivery offers the opportunity to rejuvenate clinical 
failures and repurpose existing drugs, and the US Food and Drug 
Administration has approved around 60 nanoparticle formulations to 
date.3 Correspondingly, as increasingly sophisticated formulations 
enter development there is a growing need for analytical research 
tools and quality-control methods to characterise nanoparticles and 
their cargo at the atomic and molecular levels and to explore the 
mechanisms of drug delivery.     
Here we use 19F NMR as a sensitive probe of the molecular 
orientations of fluorine-containing drugs as they undergo anisotropic 
motion within a reconstituted high-density lipoprotein (rHDL) 
nanoparticle formulation. rHDL nanoparticles are attractive drug 
delivery vehicles that are well-tolerated in vivo, do not invoke an 
immune response and are capable of delivering lipophilic drugs to 
tissues via specific receptors.4, 5 The clinically-tolerated rHDL 
preparations CER-001 and CSL112 are nanodiscs comprising a 
phosphatidylcholine or sphingomyelin/phosphatidylglycerol lipid 
bilayer surrounded by a helical belt of recombinant apolipoprotein 
A-I (apoA-I), the 28-kDa major protein component of natural HDL.6, 7 
The position of the native cholesteryl ester (CE) cargo within the core 
of natural HDL is important for cellular transfer via the SR-B1 
receptor,8 and packaging by the nanodiscs may similarly influence 
the cellular uptake of drugs. Transfer of CE, vitamins and drugs from 
HDL into cells is in part mediated by scavenger receptors (e.g., SR-
B1), which have channel-forming extracellular domains that 
selectively bind certain lipophilic molecules and transfer them to the 
cytoplasm.9  A drug’s orientation within the rHDL lipid matrix will 
influence how the drug is presented to a receptor and so may affect 
the rate and selectivity of transfer.10    
We exploit 19F chemical shifts and 1H-19F dipolar couplings11 to 
compare the orientations of two lipophilic fluoroaromatic drugs 
within the lipid bilayer component of rHDL particles.  We chose as our 
drugs two fluorine-bearing statins, fluvastatin (logP = 4.17) and 
rosuvastatin (logP = 1.47) (Scheme 1); statin-loaded rHDL 
nanoparticles have been shown to reduce atherosclerotic lesions in 
an atherosclerosis mouse model.12  We prepared nanoparticles of 
rHDL comprising palmitoyl oleoyl phosphatidylcholine (POPC), 
fluvastatin or rosuvastatin and full-length apoA-I in a 100:10:1 molar 
ratio using a detergent-mediated dialysis method. Native gel 
electrophoresis indicates that the particle size ranges from 8 - 10 nm 
and transmission electron microscopy (TEM) confirms the 
characteristic discoidal morphology of the particles (Figure 1A, left 
and middle). A circular dichroism (CD) spectrum (Figure 1A, right) 
indicates that apoA-I adopts the expected predominantly (84 %) α-
helical conformation. It should be noted that similar-sized truncated 
apoA-I/lipid nanodiscs are widely used in biological NMR to analyse 
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Scheme 1. Chemical structures of fluorine-containing statins. 
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the structures of membrane-embedded proteins, as their rapid 
tumbling times conveniently provide high-resolution spectra.13 Here 
the isotropic molecular tumbling of nanodiscs in solution would 
obscure the effects of local anisotropic motions of the drug that 
convey information about drug orientation, so we precipitated the 
nanoparticles from aqueous solution to eliminate particle tumbling. 
The fluid hydrated lipid bilayer is preserved in the precipitate, as 
indicated by a 31P NMR spectrum of the POPC phosphate groups with 
the characteristic 45 ppm width and axially symmetric line shape 
(Figure 1B, left).14, 15 A 15N magic angle spinning NMR spectrum of 
precipitated rHDL particles constructed from 15N-labelled apoA-I 
confirms that protein is also present in the precipitate and the 
backbone chemical shifts are consistent with the expected 
predominantly α-helical structure (Figure 1B, right).
Statins embedded in the rHDL lipid bilayer will undergo 
anisotropic motions that scale the 19F chemical shift anisotropy in a 
predictable way that depends on the drug’s orientation in the planar 
matrix.11 Molecules rotate about a principal axis that runs parallel 
with the bilayer normal and the NMR line shape is sensitive to the 
orientations of the 19F chemical shift tensor elements δ11, δ22 and δ33 
relative to this axis, as defined by angles α and β (Figure 1C). If the 
chemical shift tensor orientation relative to the molecular geometry 
is known, one can relate the measured chemical shift anisotropy to 
the average orientation of the drug in the lipid bilayer. DFT 
calculations predict that the 19F chemical shift tensor is oriented with 
the least-shielded component δ11 exactly in plane with the aromatic 
ring and δ22 directed along the fluorine-carbon bond (Figure S1), as 
seen for other fluorophenyl compounds.11 Additional random 
motional fluctuations of the molecule about the two axes 
perpendicular to the main axis must also be considered in the 
analysis, as must internal rotations of the fluoroaromatic ring (Figure 
1C). Random fluctuations are described by an order parameter, Smol, 
which describes the maximum angular excursion θ from the principal 
axis through Smol = cos(θ)
Proton-decoupled 19F NMR spectra confirm that the two 
statins are present in the rHDL formulations (fluvastatin in 
Figure 2A and rosuvastatin Figure S2A). Whereas the 19F 
chemical shift anisotropy Δδ of the two statins in the solid state 
is ~60 ppm, with an asymmetry parameter η of ~0.7 (Figure S1 
and Table S1), the spectra of the rHDL formulations indicate an 
approximate 10-fold reduction in the observed anisotropy and 
an apparent axially symmetric chemical shift tensor (η = 0) 
(Table S2). These features confirm that the molecules undergo 
anisotropic rotation and give a scaled chemical shift anisotropy, 
Δδav, of 6.2 ppm for fluvastatin and 8.3 ppm for rosuvastatin. 
The absence of narrow peaks at the isotropic chemical shifts of 
the statins indicates that the drugs are not distributed between 
the nanoparticles and the residual aqueous phase but are 
confined within the lipid matrix.  Calculations of the expected 
value of Δδav for different values of α and β (varying each from 
0° to 180°) reveal that the maximum possible value of Δδav is 4.6 
ppm for fluvastatin and 4.9 ppm for rosuvastatin (Figure S2B) 
when rotation of the fluorophenyl ring is considered in addition 
to the overall molecular rotation. These Δδav values are smaller 
than the observed values and hence free rotation of the 
fluorophenyl ring must be slow on the NMR (s) time scale, 
possibly because of a high energy barrier resulting from steric 
clashes between the aromatic and heptenoic acid protons.
Figure 1. Encapsulation of statins within rHDL particles. A: Native gel electrophoresis (left) and TEM (middle) confirm the presence of rHDL particles approximately 8 - 10 
nm in diameter in the absence or presence of fluvastatin. CD spectroscopy (right) indicates the presence of predominantly helical protein. B: 31P NMR (left) confirms the 
presence of lamellar POPC lipids in PEG precipitated rHDL and 15N CP-MAS NMR (right) indicates that the helical structure of apoA-I is retained in the PEG precipitate. The 
red line is a simulated line shape comprising the predicted backbone 15N chemical shifts of all residues of apoA-I in a fully helical conformation. C: Rapid dynamics of a 
statin embedded in a lipid bilayer of rHDL that may scale the 19F chemical shift anisotropy. The principal axes of the 19F chemical shift tensor are shown with the origin at 
the centre of mass of the molecule. Angles α and β define the 19F principal axes relative to the principal rotation axis, which is parallel with the bilayer normal, and the axis 
of the aromatic ring rotation is parallel with the direction of 19F chemical shift tensor component δ22. Off-axis excursions are represented by an order parameter Smol = 
cos(θ).
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Figures 2B and S3B show that the Δδav values measured 
from the proton-decoupled spectra are consistent with a 
continuum of α and β values, with α ranging from 0 - 180° and 
β ranging from 40° - 65°. To restrict further the range of possible 
molecular orientations defined by these angles, we obtained 
proton-coupled 19F NMR spectra of the rHDL formulations to 
obtain line shapes that are modulated by 1H-19F dipolar 
interactions within the statin fluoroaromatic ring. The 
magnitude of the dipolar couplings is, like Δδav, sensitive to the 
orientation of the statins relative to their principal rotation axis. 
We calculated the dynamically-averaged dipolar coupling 
constants, dav, for 36 discrete pairs of α and β along the 
continuum (Figures 2C and S3C). We then simulated a series of 
proton-coupled 19F NMR line shapes based on the calculated 
couplings and the measured Δδav values for each statin to find 
the values of α and β achieving the closest agreement with the 
experimental line shapes according to chi-square analysis 
(Figures 2D and S3-S5). For fluvastatin, the closest agreement is 
obtained with four [α, β] combinations and for rosuvastatin 
with two [α, β] combinations (Table S3, Figures 2E and S2E). 
Discrepancies between the simulated and experimental spectra 
may reflect minor contributions from longer-range inter- and 
intramolecular couplings, which could not be included in the 
simulations.  For each pair of angles, errors of ±5° in α and ±1.5° 
in β reflect the uncertainty in Smol, the true value of which we 
assume lies between the extremes of 0.5 (θ = 60°) and 1.0 (θ = 
0°). The value of Smol reported for sterol molecules is ~0.8.16, 17  
After taking into consideration the out-of-plane 
fluorophenyl ring conformation of the two statins, as 
determined from crystal structures and by energy minimisation 
(Figure S6) we translated the angles into two possible mean 
Figure 2. The average orientations of statins with the lipid bilayers of rHDL particles from 19F NMR lineshape analysis. A: Spectrum of fluvastatin in rHDL (black). The value 
of Δδav (6.1 ppm) was obtained by least-squares fitting of a simulated lineshape (red). B: The measured Δδav is consistent with the pairs of α and β values shown by the 
continuous lines. Discrete values of α (in 5° increments) and corresponding β values (denoted by the filled and open circles, in 10° increments for clarity) were used to 
simulate proton-coupled spectra as described below. C: Each of the discrete [α, β] pairs define a specific statin orientation relative to a principal axis of rotation. From each 
orientation the rotationally-averaged dipolar couplings dav between 19F and the 4 protons (H1-H4) in the fluorophenyl ring were calculated. D: Proton-coupled spectra were 
simulated for each [α, β] pair and the corresponding dipolar coupling values. Chi-squared values represent the agreement between each simulated spectrum and the 
experimental dipolar-coupled spectrum. E: The line of closest agreement with the proton-coupled spectrum (chi-squared minimum) is consistent with 4 [α, β] values given 
in Table S3. F: Average orientations of fluvastatin and rosuvastatin in rHDL bilayers. Vertical arrows denote the principal axis of rotation, which is parallel with the bilayer 
normal. 
Figure 3. Proton-decoupled and proton-coupled 19F NMR spectra of fluvastatin (A) 
and rosuvastatin (B) embedded in POPC MLVs. Experimental spectra (black) are 
overlaid with best-fitting simulated-two component lineshapes (red). The two 
values of Δδav obtained from the two components of each spectrum are given in 
Table S2 and the values of α and β calculated from the spectra are given in Table 
S3. Dotted lines indicate the isotropic chemical shifts.
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orientations of fluvastatin about its principal axis of rotation in 
the lipid bilayer (Figure 2F, top) and one orientation of 
rosuvastatin (Figure 2F, bottom), as well as their mirror images. 
The two molecules adopt similar orientations in the lipid matrix. 
Solution-state 1H-1H NOESY NMR spectra of fluvastatin in 
dodecylphosphocholine micelles revealed cross peaks between 
the aromatic protons of the drug and headgroup and 
hydrocarbon chain protons of the lipid, suggesting that the 
aromatic ring serves as a hydrophobic anchor and the 
dihydroxyheptenoic acid is associated with the lipid 
headgroups.18, 19 Here, a NOESY NMR spectrum of fluvastatin in 
POPC multilamellar vesicles (MLVs), obtained with magic-angle 
spinning, revealed cross peaks between protons in the 
fluoroaromatic ring and hydrocarbon chain protons (Figure S7), 
confirming that the ring serves as a hydrophobic anchor.   This 
may explain the restricted rotation of the ring. 
Lastly, we asked whether the statins adopt similar orientations in 
spherical, protein-free POPC MLVs. In contrast to the rHDL spectra, 
the 19F proton-decoupled and coupled spectra of the MLVs (Figure 3) 
each comprise two components in approximately equal proportion. 
The narrow component in the spectra of rosuvastatin (Figure 3B) 
does not arise from an isotropic population of the drug (i.e., that is 
rapidly tumbling in solution or smaller vesicles) because the 
component is offset from the isotropic chemical shift. All spectra 
could be simulated by two anisotropic components, one with Δδav > 
0 and the other with Δδav < 0 (Table S2), indicating that each statin 
adopts two different average orientations in the MLV bilayers. The 
spectra illustrate how highly sensitive this method is to minor 
alterations in molecular orientation, because analysis of the two 
spectral components for each statin reveals very close values of α 
and β for the molecules in each population (Table S3). The sensitivity 
of the α and β values to orientation also reveal that fluvastatin and 
rosuvastatin adopt very subtly different orientations in POPC MLVs 
and in rHDL. 
There is still much to learn about the molecular packaging of 
drugs by nanoparticles, yet these details may influence how drugs 
transfer to the recipient tissue. Here we have shown an NMR method 
exploiting chemical shifts and dipolar couplings to determine the 
mean orientations of drugs within the lipid matrix of rHDL 
nanoparticles. About 30 % of small molecule drugs contain fluorine 
20 and so the 19F NMR method could be applicable to up to 750 
approved and 1600 experimental drugs, depending on their 
suitability for HDL encapsulation. The high sensitivity of the 19F NMR 
line shape to just minor adjustments of molecular orientation makes 
it a useful method for structure-activity studies relating the 
molecular orientations of drugs to the rates of transfer to tissue, and 
for analysing the reproducibility of formulations.
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